← Back to Search

Antihistamine

Desloratadine for Inflammation

N/A

Recruiting

Led By Lynneth Stuart-Hill, PhD

Research Sponsored by University of Victoria

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up before, immediately following, and 2-hours following exertional heat strain

Awards & highlights

Study Summary

This trial will compare the effects of the antihistamine drug desloratadine on firefighters' inflammatory responses to heat stress.

Eligible Conditions

Inflammation
Firefighter PPE
Heat Exhaustion

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ before, immediately following, and 24, 48, and 72-hours following exertional heat strain

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~before, immediately following, and 24, 48, and 72-hours following exertional heat strain

This trial's timeline: 3 weeks for screening, Varies for treatment, and before, immediately following, and 24, 48, and 72-hours following exertional heat strain for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body Weight Changes

Change in serum cortisol

Body Weight Changes

+1 more

Secondary outcome measures

Change in body mass

Differences in core body heat storage

Other outcome measures

Differences in Cerebral Blood Flow

Differences in brain blood oxygenation of prefrontal cortex

Differences in heart rate (HR) and heart rate variability (HRV)

Side effects data

From 2007 Phase 4 trial • 886 Patients • NCT00264303

Headache

Somnolence

Fatigue

Abdominal pain upper

Nausea

100%

80%

60%

40%

20%

Study treatment Arm

Levocetirizine 5 mg

Desloratadine 5 mg

Trial Design

3Treatment groups

Experimental Treatment

Group I: No InterventionExperimental Treatment1 Intervention

No intervention: neither drug nor placebo

Group II: Inert PlaceboExperimental Treatment1 Intervention

Placebo 10mg compounded to oral pill

Group III: DesloratadineExperimental Treatment1 Intervention

Desloratadine (Aerius) 10mg compounded to oral pill

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Placebo

1995

Completed Phase 3

~2670

Desloratadine

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of VictoriaLead Sponsor

56 Previous Clinical Trials

11,479 Total Patients Enrolled

Lynneth Stuart-Hill, PhDPrincipal InvestigatorUniversity of Victoria

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor seeking participants over quarter of a century old?

"In accordance with the trial requirements, applicants must be between 19 and 50 years old."

Answered by AI

How many patients have enrolled in this clinical research endeavor?

"Affirmative. According to clinicaltrials.gov, this medical trial is actively recruiting volunteers, having first been posted on July 1st 2022 and updated most recently on the 4th of that same month. A total of 12 participants from one site need to be enrolled in order for the study to commence."

Answered by AI

Is this trial open to new participants?

"Confirmed. Clinicaltrials.gov documents that this trial began recruiting patients on July 1st 2022, and is still actively seeking participants as of July 4th 2022. Currently, 12 volunteers are required to complete the study from one site."

Answered by AI

What types of individuals are eligible to participate in this medical experiment?

"This trial is recruiting 12 individuals between 19 and 50 years of age suffering from inflammation. In order to qualify, potential participants must be willing to adhere to the study requirements as outlined in a signed informed consent form, demonstrate physical fitness through completion of the PAR-Q questionnaire, have no allergies or current use of H1 histamine receptor antagonists, possess an adequate VO2Max level (>35 mL/kg/min), and meet all 'Category A' health requirements listed by the National Fire Protection Association (NFPA) 1582."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain

2022. "Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05446480.